Myeloma UK has joined forced with Edinburgh-based charity VOCAL (Voice of Carers Across Lothian) to offer family members and friends of myeloma patients a new free training session called, “Caring with someone with myeloma.”
Findings have been published from the MUK six clinical trial, a trial conducted as part of the Myeloma UK Clinical Trial Network. Myeloma UK Research Director, Simon Ridley, explains how the findings could help myeloma patients in the future.
Revlimid is already licensed by the EMA in all stages of relapse and as a treatment for newly diagnosed patients who are ineligible for transplant. If approved this further recommendation will extend the existing licence. The European Commission now has 60 days to issue final guidance.
Myeloma UK has voiced concerns about proposals to introduce a £20m “budget impact threshold” for new medicines approved by the National Institute for Health and Care Excellence (NICE). These proposals were set out in a joint consultation issued by NHS England and NICE. Currently there are no specific concerns about particular myeloma treatments being affected by the proposed threshold.
The SMC decision means that patients in Scotland will not be able to access either of these treatment indications routinely. Myeloma UK Policy and Public Affairs Manager, Kate Morgan commented, “Myeloma UK made a strong case to the SMC for the approval of both indications and we are very disappointed by the decision not to recommend them for use.
Patients now have better access to new medicines for rare cancer thanks to reforms to the drug approval system in Scotland, an independent review has found.
Data from the largest trial in myeloma has shown that lenalidomide could double the length of time that patients remain […]
The 58th annual ASH meeting is taking place on 3 to 6 December in San Diego, California. ASH is the most […]
Myeloma UK has been hearing from the families, friends and carers of myeloma patients as we publish findings from a […]
Researchers at the Institute of Cancer Research, London (ICR) have identified a new way to explain why a key genetic […]